- Home
- TYRA vs USNA Comparison
TYRA vs USNA Comparison
Compare TYRA & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- USNA
- Stock Information
- Founded
- TYRA 2018
- USNA 1992
- Country
- TYRA United States
- USNA United States
- Employees
- TYRA N/A
- USNA N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- USNA Medicinal Chemicals and Botanical Products
- Sector
- TYRA Health Care
- USNA Health Care
- Exchange
- TYRA Nasdaq
- USNA Nasdaq
- Market Cap
- TYRA 812.7M
- USNA 765.5M
- IPO Year
- TYRA 2021
- USNA 1996
- Fundamental
- Price
- TYRA $14.00
- USNA $33.43
- Analyst Decision
- TYRA Strong Buy
- USNA Hold
- Analyst Count
- TYRA 5
- USNA 1
- Target Price
- TYRA $31.00
- USNA $35.00
- AVG Volume (30 Days)
- TYRA 219.5K
- USNA 115.1K
- Earning Date
- TYRA 11-07-2024
- USNA 02-04-2025
- Dividend Yield
- TYRA N/A
- USNA N/A
- EPS Growth
- TYRA N/A
- USNA N/A
- EPS
- TYRA N/A
- USNA 2.83
- Revenue
- TYRA N/A
- USNA $861,973,000.00
- Revenue This Year
- TYRA N/A
- USNA N/A
- Revenue Next Year
- TYRA N/A
- USNA N/A
- P/E Ratio
- TYRA N/A
- USNA $11.79
- Revenue Growth
- TYRA N/A
- USNA N/A
- 52 Week Low
- TYRA $11.24
- USNA $33.28
- 52 Week High
- TYRA $29.60
- USNA $54.81
- Technical
- Relative Strength Index (RSI)
- TYRA 32.68
- USNA 29.46
- Support Level
- TYRA $14.65
- USNA $36.03
- Resistance Level
- TYRA $15.55
- USNA $37.69
- Average True Range (ATR)
- TYRA 0.72
- USNA 1.28
- MACD
- TYRA 0.02
- USNA -0.51
- Stochastic Oscillator
- TYRA 3.12
- USNA 2.40
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About USNA USANA Health Sciences Inc.
Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.